Affiliate networks, marketplaces and the credential they screen on

Partnership channels fail differently from payments and advertising. A processor declines you and says so. An ad account gets suspended and you notice within a day. An affiliate network just does not approve the offer, and the brand concludes that affiliate is not a good channel for them.

For telehealth, that conclusion is frequently wrong. The channel works. The credential is missing.

Who screens on it

Affiliate networks in the health vertical. Networks carry their own risk from the offers they distribute, and a network that approves a healthcare offer which later draws regulatory attention has a problem with every publisher who ran it. Certification is a cheap first filter and increasingly a required one.

Healthcare marketplaces and aggregators. Comparison sites, condition-specific marketplaces and benefits platforms list certified providers because their own users and their own payment relationships require it.

Fulfilment and logistics partners. Anybody in the chain with their own registration to protect screens the brands they serve.

Employer, benefits and payer buyers. Diligence questionnaires ask for it because a single credential answers a page of questions about vetting.

None of these will explain the gap. They will decline, or go quiet, and the loss shows up as a business development conversion problem.

What certification unlocks, and what it does not

It unlocks the screen. It gets the offer into review, gets the listing considered, gets the diligence questionnaire past its first page.

It does not carry the rest of the conversation. Networks still assess the offer's claims, the landing page, the refund history and the chargeback profile. Marketplaces still assess service quality. A certified brand with a poor cancellation flow and a high dispute rate is a certified brand that networks decline for ordinary commercial reasons.

Which is a useful framing: certification is table stakes for the conversation rather than the argument you win it with.

The risk that comes with the channel

Affiliate distribution imports a claims problem that direct marketing does not have. Publishers write their own copy, and in this vertical they write aggressively, because aggressive copy converts and the publisher is not the one holding the certification.

The material fact is that content driving into your funnel forms part of the marketing surface a certification reviewer, an ad platform and a regulator can all reach. A publisher's comparison of your compounded preparation to a brand-name drug is a comparison claim attached to your offer. Our index of FDA warning letters covering compounded GLP-1 marketing counts a misleading comparison among the violations cited most often, which is the specific claim affiliates in this category write most readily.

So the channel needs governance, and the governance is not complicated:

• Give publishers the allowlist. The same claims document your own copywriters use, with the approved phrasing for the two or three things everybody wants to say.
• Require creative approval before launch. Not after the first payout.
• Monitor what is actually live. Run your brand terms and your product terms periodically and read what comes back. Publishers change creative without asking.
• Make the contract say it. A takedown obligation with a short deadline, and the right to withhold commission on non-compliant traffic.

Brands that do this keep the channel. Brands that do not eventually lose either the channel or the certification, and usually in that order.

The domain question again

Affiliate programmes generate domains: tracking domains, publisher-built pre-sell pages, sometimes a co-branded landing page hosted by the network.

Pre-sell pages hosted by a publisher on their own domain are their site, not yours, though the claims on them are still your problem. A page you host for a partner is your domain, and if it takes intake or transacts it is a certification question. This is worth settling before the programme launches, because it changes what the exercise costs across your domain estate.

A realistic sequence

Certify the domains that receive traffic. Write the allowlist. Then open the partnership conversations, with the listing live and the creative rules ready to hand to any publisher who asks.

Opening them in the other order wastes the outreach, because the first qualifying question is the credential and the second is what your publishers are allowed to say.

The diligence pack that shortens every conversation

Partners ask for broadly the same things, so assemble them once and send them unprompted. It shortens the cycle and it signals that you have done this before.

• The certification listing link, for each domain that carries traffic.
• A one-page description of the clinical model: who prescribes, under what licences, what the intake involves, what happens when a prescriber declines.
• The dispensing pharmacy, named as an entity, with its registration type.
• The claims allowlist, which doubles as your creative brief for publishers.
• Refund, cancellation and dispute policy, with your chargeback rate if it is good.
• A named contact for compliance questions who replies within a day.

The last item is worth more than it looks. Networks and marketplaces carry risk from the offers they distribute, and a brand with a real compliance contact is easier for them to justify internally than one that routes everything through an affiliate manager.

When to walk away from a partner

Some publishers are worth declining. A publisher who will not accept creative approval, who runs claims you have asked them to remove, or who buys your brand terms with copy you have never seen, is generating traffic that costs more than it earns.

The arithmetic is simple: the commission on that traffic is bounded and the exposure is not. A single publisher page comparing your compounded preparation to a brand-name drug can reach a regulator, an ad platform reviewer and a certification monitor. Cutting the publisher is cheap. Explaining their page is not.